unbekannter Gast

Posch, Christian#

Dermatologe

Christian Posch
Bild 'CPosch'

* 30.12.1981, Vienna
Nationality Austria
Marital status single

University Studies
#

Music#

1998-2000 Violoncello, Private University, Conservatorium Vienna (Prof. J. Bayrow)
2000-2001 Violoncello, University for Music and Performing Arts, Vienna (Prof. V. Erben)

Medicine#

2001-2007 Human Medicine, Medical University of Vienna, Additional medical training
2003-2004 “Anatomia practica” (Prof. E.B. Krammer)
2004-2005 “Transplantation medicine” (Prof. T. Weckerle)
2006-2007 “Management of respiratory problems” (Prof. O. Plattner)

Science#

2011-ongoing Ph.D. Student (Applied Medical Science), Medical University of Vienna 

Positions and Employment#

2001-2007 M.D. Student, Medical University of Vienna, Austria
2007-2010 Resident in General Medicine, State Hospital Moedling, Austria
2010-present Resident in Dermatology, The Rudolfstiftung University Hospital Vienna, Austria
2011-present Ph.D. Student (Applied Medical Science), Medical University of Vienna, Austria
2011-2014 Postdoctoral Research Fellow, University of California San Francisco, CA
2014-present Research Fellow in Dermatology, Harvard Medical School, Department of Dermatology, Brigham and Women’s Hospital, Boston, MA

Scholarships, Funding, Awards#

2011 TOP-Foreign Exchange Scholarship, Government of Lower Austria
2011 Travel Grant, American Academy of Dermatology
2011-2012 Research Scholarship, Society of Dermatology and Venerology, Rudolfstiftung Hospital
2012-2013 Max Kade Fellowship, Austrian Academy of Sciences/ MAX KADE Foundation Inc. NY (awarded to outstanding Austrian scientists in support of research at top US institutions)
2012 Travel Grant, PhD-Retreat, Society for Investigative Dermatology
2012 Travel Grant, Office of Science & Technology Austria, Washington, DC
2013 Travel Grant, PhD-Retreat, International Investigative Dermatology
2013 Klaus Wolff Fellowship, Harvard Medical School
2013 UNILEVER Award, Austrian Society of Dermatology and Venerology (best basic experimental research project by an Austrian Dermatologist in 2013)
2013 Travel Grant, Office of Science and Technology Austria, Washington, DC 2013-2014 René Touraine International Fellowship, René Touraine Foundation (distinguished European fellowship for exchange and international collaboration) 2014 Travel Grant, European Society for Dermatological Research 2014 Travel Grant, Academy for Future Leaders in Dermatology Retreat, European Society for Dermatological Research 2014 Outrun the Sun Melanoma Research Scholar Award

Societies#

2010-present Member, Society for Dermatology and Venerology, The Rudolfstiftung Hospital
2010-present Member, Austrian Society of Dermatology and Venerology (OeGDV)
2011-present Member, Austrian Scientists and Scholars in North America (ASCINA)
2012-present Member, European Society for Dermatological Research (ESDR)
2012-present Member, European Association of Dermatolo-Oncology (EADO)
2012-present Member, Society for Investigative Dermatology (SID)

Publications#

27. Posch C, Vujic I, Sanlorenzo M, Ma J, Kim ST, Arneson DV, Lai K, Zekhtser M, Green G, Esteve-Puig R, Oses-Prieto J, Burlingame A, Rappersberger K, Ortiz-Urda S. NRAS ≠ NRAS – Signaling of different NRAS mutations and potential clinical implications. under review at Molecular and Cellular Proteomics
26. Posch C, Cholewa B, Vujic I, Sanlorenzo M, Ma J, Kim ST, Rappersberger K, Ahmad N, Oritz-Urda S. Synergistic effects on viability and dual G1 and G2/M cell cycle arrest in NRAS mutant melanoma with MEK/Plk1 inhibition. under review at JID
25. Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew: UV Measurements in Flying Airplanes. JAMA Dermatol. 2014 Dec 17.
24. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2014 Nov 25.
23. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec;71(6):1102-1109
22. Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza A, Ortiz-Urda S. Detection of GNAQ Mutations and Reduction of Cell Viability in Uveal Melanoma Cells with Functionalized Gold Nanoparticles. accepted for publication at Biomedical Microdevices 2014 October 8.
21. Vujic I, Posch C, Sanlorenzo M, Yen A, Tsumura A, Kwong A, Feichtenschlager V, Rappersberger K, Ortiz-Urda S. Mutant NRAS Q61 shares signaling similarities across various cancer types - potential implications for future therapies. Oncotarget 2014 August 5;

20. Monshi B, Posch C, Vuic I, Sesti A, Sobotka S, Rappersberger K. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long term-follow up of 11 patients. J Am Acad Dermatol 2014 Jul 9. pii: S0190-9622(14)01526-6. doi: 10.1016/j.jaad.2014.05.039. (Epub ahead of print)

19. Latorre A*, Posch C*, Garcimartin J, Zekhtser M, Ma J, Celli A, Rappersberger K, Ortiz-Urda S, Somoza A. DNA stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale. 2014 Jul 7;6(13):7436-42 (*authors contributed equally)

18. Sanlorenzo M, Posch C, Vujic I, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew: UV measurements in flying planes. Accepted for publication JAMA Dermatol. 2014 Oct 23

17. Sanlorenzo M, Wehner MR, Linos E, Kornak J, Wolfgang K, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver J E, Ortiz-Urda S. The Risk of Melanoma in Pilots and Cabin Crew - A Meta-analysis. JAMA Dermatol. 2014 Sep 3

16. Marker M, Vujic I, Mühlehner D, Posch C, Monshi B, Breier F, Steiner A, Rappersberger K. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. J Eur Acad Dermatol Venereol. 2014 Aug 4.

15. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 1;15(6):665-74 (Epub ahead of print) Review

14. Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K. Mycoplasma pneumoniae-associated mucositis – case report and systematic review of literature. J Eur Acad Dermatol Venereol, 2014 Feb 17. (Epub ahead of print) doi: 10.1111/jdv.12392

13. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18;110(6):1427-32

12. Latorre A*, Posch C*, Garcimartin J, Ortiz-Urda S, Somoza A. Single-Point Mutation Detection in RNA Extracts using Gold Nanoparticles Modified with Hydrophobic Molecular Beacons. Chem Commun (Camb). 2014 Mar 21;50(23):3018-20 (*authors contributed equally)

11. Posch C, Pinney E, Ortiz-Urda S, Montes-Camacho M, Naughton GK. Human Multipotent Stem Cell Proteins Induce Apoptosis in Skin Cancer Cells. Journal of Cancer Therapy. 2013 July 4. doi:10.4236/jct.2013.46A1001

10. Posch C, Ortiz-Urda S. NRAS mutant melanoma – undrugable? Oncotarget. 2013 Apr;4(4):494-5. Review

9. Weingast J, Scheibboeck C, Wurm EMT, Ranharter E, Porkert S, Dreiseitl S, Posch C, Binder M. A prospective study of mobile phones for dermatology in a clinical setting. J Telemed Telecare. 2013 Jun;19(4):213-8

8. Posch C, Ortiz-Urda S. Abnormal Pigmentation. In: GEMSoft (electronic media). Lin M, Chin RL (eds). GEMSoft (General Emergency Medicine Software).Queensland, Australia: Pemsoft Pty Ltd. Accepted for publication, 2013.

7. Posch C, Ortiz-Urda S. Drug reactions. In: GEMSoft (electronic media). Lin M, Chin RL (eds). GEMSoft (General Emergency Medicine Software).Queensland, Australia: Pemsoft Pty Ltd. Accepted for publication, 2013.

6. Posch C, Moslehi H, Feeney L, Green G, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon M, Phillips T, Daud A, McCalmont T, LeBoit P, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20.

5. Posch C, Walochnik J, Gschnait A, Feichtinger H, Rappersberger K. Kala Azar – Lethal course of visceral leishmaniasis. Hautarzt. 2012 Dec; 63(12):947-51.

4. Posch C, Kaulfersch W, Rappersberger K. Cryopyrin-Associated Periodic Syndrome. Pediatr Dermatol. 2012 Aug 14. doi: 10.1111/j.1525-1470.2012.01812.x. (Epub ahead of print)
3. Posch C, Vesely M, Monshi B, Feichtinger H, Cziegler K, Rappersberger K. Animal-type melanoma - tumor cell invasion of dermal lymphatics and molecular identification of lymph node metastasis. J Dtsch Dermatol Ges. 2012 Jan;10(1):38-41.

2. Posch C, Walochnik J, Schuller-Lukic B, Weihsengruber F, Geppert F, Rappersberger K. Perianal ulcer - amebiasis cutis. J Dtsch Dermatol Ges. 2011 Aug;9(8):649-50.

1. Hecking M, Kainz A, Schillinger M, Posch C, Birsan T, Rasoul-Rockenschaub S, Böhmig GA, Schmaldienst S, Watschinger B, Hörl WH, Mühlbacher F, Säemann MD. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. Transpl Int. 2008 Mar;21(3):223-33.

Accepted Abstracts#

13. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low dose inhalation of Interleukin-2 (IL-2) bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
 Annual meeting of the Austrian Society of Dermatology and Venerology, 21.-23.11.2014, Vienna
 Inflammatory Skin Disease Summit, 19.-21.11.2014, Vienna

12. Posch C, Vujic I, Sanlorenzo M, Ma J, Kim ST, Arneson DV, Lai K, Zekhtser M, Green G, Esteve-Puig R, Oses-Prieto RJ, Burlingame A, Ortiz-Urda S. NRAS ≠ NRAS – signaling of different NRAS mutations and potential clinical implications.
 Annual meeting of the European Society for Dermatologic Research, 10.9.-13.9.2014 Copenhagen, DEN
 Annual meeting of the Austrian Society of Dermatology and Venerology, 21.-23.11.2014, Vienna

11. Pinney E, Montes-Camacho M, Brintle K, Posch C, Menen RS, Easter D, Bouvet M, Hoffman RM, Naughton G. Sub-fractions of conditioned medium from a neo-natal fibroblast, three dimensional bioreactor system, has significant anti-oncogenic activity.  AACR Annual Meeting 5.4-9.4.2014 San Diego, USA

10. Algazi AP, Posch C, Ortiz-Urda S, Cockerill A, Munster PN, Daud A. A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.  Annual Meeting of the American Society of Clinical and Oncology, ASCO 30.5. – 3.6.2014 Chicago, USA

9. Monshi B, Posch C, Vujic I, Sesti A, Sobotka S, Jungbauer L, Rappersberger K. Efficacy of intravenous immunoglobulines in livedoid vasculopathy; a retrospective study of 29 disease episodes in 11 patients.  Annual meeting of the Austrian Society of Dermatology and Venerology, 22.-24.11.2013, Vienna

8. Posch C, Latorre A, Garcimartin J, Zekhtser M, Ma J, Celli A, Rappersberger K, Ortiz-Urda S, Somoza A. DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics.  Annual meeting of the Austrian Society of Dermatology and Venerology, 22.-24.11.2013, Vienna

7. Algazi AP, Posch C, Ortiz-Urda S, Cockerill A, Munster PN, Daud A.BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: 2 cases.  Annual meeting American Society of Clinical Oncology (ASCO), 31.5.-4.6.2013

6. Posch C, Moslehi H, Feeney L, Green G, Ebaee A, Feichtenschlager V, Peng L, LeBoit P, Ortiz-Urda S.Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.  Annual meeting of the Austrian Society of Dermatology and Venerology, 19.-21.11.2012, Vienna  Annual meeting of the Society for Melanoma Research, 8.-11.11.2012, Hollywood, California USA  International Investigative Dermatology 2013, 8.-11.5.2013, Edinburgh, Scotland

5. Posch C, Somoza A, Latorre A, Crosby M, Moslehi H, Green G, Ortiz-Urda S.Mutation analysis and treatment of Gq mutated uveal melanoma cells.  Annual Meeting of the Society for Investigative Dermatology, 9.-12.5.2012, Raleigh, North Carolina, USA

4. Latorre A, Posch C, Ortiz-Urda S, Somoza A.DNA stabilized Gold nanoparticles as delivery System.  Biennial Meeting of the Chemical Biology Group of the Royal Society of Chemistry, 8.-9.3.2012, Santiago de Compostella, Spain

3. Weingast J, Ranharter E, Posch C, Scheibboeck C, Pehamberger H, Binder M. The use of cellular phones in tele-dermatology: A prospective study.  EADV, 6.-10. October Gothenburg, Congress of the European Association of Dermatology and

2. Posch C, Monshi B, Feichtinger H, Cziegler K, Rappersberger K.Animal type melanoma – tumor cell invasion of dermal lymphatics and lymph node metastasis. OeGDV, 19.-21.11.2010, Vienna, Congress of the Austrian Society of Dermatology and Venerology

1. Stella A, Harmankaya K, Posch C, Ranharter E, Scheibboeck C, Stolkovich S, Pehamberger H, Binder M.Influence of particulate matter (PM) on children’s skin – ecological comparative study of Austrian elementary school children.  European Congress of Pediatric Dermatology, 14.-18.5.2008 Athens  EADV, 17.-21.9.2008 Paris, Congress of the European Association of Dermatology and Venerology  OeGDV, 28.-30.11.2008 Vienna, Congress of the Austrian Society of Dermatology and Venerology